Lucid Diligence Brief: Cantargia nadunolimab in MDS and AML
Lucid Diligence Brief: Cantargia nadunolimab in MDS and AML Professional…
In Vivo CAR-T: Stress-Testing the Lilly–Kelonia Deal with AI-Powered Wargaming
Why the Lilly–Kelonia Deal Matters for In Vivo CAR-T Download the…
Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash
Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash…
Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in Sarcoma
Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in…
Lucid Diligence Brief: Vir Biotechnology $1.37B collaboration with Astellas
Lucid Diligence Brief: Vir Biotechnology $1.37B collaboration with Astellas…
Lucid Diligence Brief: Telix / Regeneron radiopharma collaboration
Lucid Diligence Brief: Telix / Regeneron radiopharma collaboration Professional…
Lucid Diligence Brief: Syneron Bio completion of $150 million Series B
Lucid Diligence Brief: Syneron Bio completion of $150 million Series B…
Lucid Diligence Brief: MSD to acquire Terns
Lucid Diligence Brief: MSD to acquire Terns Professional audiences only. Not…
Lucid Diligence Brief: Kupando adds €10 million to its Series A for Toll-like receptor assets
Lucid Diligence Brief: Kupando adds €10 million to its Series A for Toll-like…
Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for TCR-mimetics
Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for…
Lucid Diligence Brief: Enodia Therapeutics Kezar Sec61 deal
Lucid Diligence Brief: Enodia Therapeutics Kezar Sec61 deal Professional…
Lucid Diligence Brief: Agilent acquires Biocare Medical for $950 million
Lucid Diligence Brief: Agilent acquires Biocare Medical for $950 million…


